|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy显示文摘Irritable bowel syndrome(IBS) is the most frequently diagnosed functional gastrointestinal disorder in primary and secondary care. It is characterised by abdominal discomfort, pain and changes in bowel habits that can have a serious impact on the patient's quality of life. The pathophysiology of IBS is not yet completely clear. Genetic, immune, environmental, inflammatory, neurological and psychological factors, in addition to visceral hypersensitivity, can all play an important role, one that most likely involves the complex interactions between the gut and the brain(gut-brain axis). The diagnosis of IBS can only be made on the basis of the symptoms of the Rome Ⅲ criteria. Because the probability of organic disease in patients fulfilling the IBS criteria is very low, a careful medical history is critical and should pay particular attention to the possible comorbidities.Nevertheless, the severity of the patient's symptoms or concerns sometimes compels the physician to perform useless and/or expensive diagnostic tests, transforming IBS into a diagnosis of exclusion. The presence of alarming symptoms(fever, weight loss, rectal bleeding, significant changes in blood chemistry), the presence of palpable abdominal masses, any recent onset of symptoms in patient aged over 50 years, the presence of symptoms at night, and a familial history of celiac disease, colorectal cancer and/or inflammatory bowel diseases all warrant investigation. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. This review examines and discusses the pathophysiological aspects and the diagnostic and therapeutic approaches available for patients with symptoms possibly related to IBS, pointing out controversial issues and the strengths and weaknesses of the current knowledge. | Massimo Bellini Dario Gambaccini Cristina Stasi Maria Teresa Urbano Santino Marchi Paolo Usai-Satta | 2014 | World Journal of Gastroenterology2014，20，27： | 37 |
| 2 | Hydroxytryptamine transporter gene-linked polymorphic region(5HTTLPR)is associated with delusions in Alzheimer’s disease显示文摘Background:Serotoninergic pathways underlying delusion symptoms in Alzheimer’s disease(AD)have not been fully clarified.5-Hydroxytryptamine transporter gene-linked polymorphic region(5-HTTLPR)is a variable number tandem repeats in the promoter region of serotonin transporter encoding-gene affecting transcription.Methods:We investigated the association of 5-HTTLPR with delusions in a total of 257 consecutive patients clinically diagnosed as AD according to the National Institute on Aging-Alzheimer’s Association criteria.All participants underwent a comprehensive evaluation with a standardized comprehensive geriatric assessment and Neuropsychiatric Inventory.Results:Delusion symptoms were observed in 171 patients(66.54%).In respect to AD patients without delusions,AD patients with delusions showed a low prevalence of S-plus carriers(5-HTTLPR-L/S+5-HTTLPR-S/S genotypes)[p<0.001;odds ratio(OR)=0.240,95% confidence interval(CI)=0.121–0.471].Logistic regression analysis adjusted for the apolipoprotein E polymorphism showed that in AD patients with delusions the presence of an 5-HTTLPR-S allele may reduce disease duration(p=0.005;OR=0.680,95% CI=0.522–0.886)and increase aberrant motor activity(p=0.013;OR=2.257,95% CI=1.195–4.260).The present findings suggested that 5-HTTLPR might be associated with delusions in AD.S-plus carriers might be associated with protective effect against delusions in AD.Conclusions:More studies on wider samples of high selected demented patients are needed to confirm our results.However,the present findings suggested that a genetic factor related to serotonin metabolism might exert a protective role on the clinical expression of neuropsychiatric clusters in AD with important implications regarding mechanisms underlying delusions and their possible treatment across the AD and dementia spectrum. | Grazia D’Onofrio Francesco Panza Daniele Sancarlo Michele Lauriola Mariangela P.Dagostino Giulia Paroni Madia Lozupone Antonio Mangiacotti Paola Bisceglia Carolina Gravina Maria Urbano Filomena Addante Francesco Paris Leandro Cascavilla Antonio Greco Davide Seripa | 2019 | Translational Neurodegeneration2019，8，1： | 2 |
| 3 | Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk显示文摘Pre-diabetes, which is typically defined as blood glucose concentrations higher than normal but lower than thediabetes threshold, is a high-risk state for diabetes and cardiovascular disease development. As such, it represents three groups of individuals: Those with impaired fasting glucose(IFG), those with impaired glucose tolerance(IGT) and those with a glycated haemoglobin(HbA1c) between 39-46 mmol/mol. Several clinical trials have shown the important role of IFG, IGT and HbA1c -pre-diabetes as predictive tools for the risk of developing type 2 diabetes. Moreover, with regard to cardiovascular disease, pre-diabetes is associated with more advanced vascular damage compared with normoglycaemia, independently of confounding factors. In view of these observations, diagnosis of pre-diabetes is mandatory to prevent or delay the development of the disease and its complications; however, a number of previous studies reported that the concordance between pre-diabetes diagnoses made by IFG, IGT or HbA1c is scarce and there are conflicting data as to which of these methods best predicts cardiovascular disease. This review highlights recent studies and cur-rent controversies in the field. In consideration of the expected increased use of HbA1c as a screening tool to identify individuals with alteration of glycaemic homeo-stasis, we focused on the evidence regarding the ability of HbA1c as a diagnostic tool for pre-diabetes and as a useful marker in identifying patients who have an increased risk for cardiovascular disease. Finally, we reviewed the current evidence regarding non-traditional glycaemic biomarkers and their use as alternatives to or additions to traditional ones. | Antonino Di Pino Francesca Urbano Salvatore Piro Francesco Purrello Agata Maria Rabuazzo | 2016 | World Journal of Diabetes2016，7，18： | 2 |
| 4 | Continuous renal replacement therapy in children after cardiac surgery显示文摘 | Maria José Santiago Jesús López-Herce Javier Urbano Maria José Solana Jimena del Castillo Amelia Sánchez Jose María Bellón | 2013 | The Journal of Thoracic and Cardiovascular Surgery2013，，2： | 1 |
| 5 | Polymorphism analysis in genes of the somatotropic axis in Nellore cattle selected for growth显示文摘 | Diercles Francisco Cardoso Fábio Ricardo Pablos de Souza Gregório Miguel Ferreira de Camargo Patrícia Dias da Silva Fonseca Larissa Fernanda Simielli Fonseca Camila Urbano Braz Arione Augusti Boligon Maria Eugênia Zerlotti Mercadante Lucia Galv?o de Albuq | 2014 | Gene2014，，2： | 1 |
| 6 | Continuous Renal Replacement Therapy in Children after Cardiac Surgery显示文摘 | Maria José Santiago Jesús López-Herce Javier Urbano Maria José Solana Jimena del Castillo Amelia Sánchez Jose María Bellón | 2013 | The Journal of Thoracic and Cardiovascular Surgery2013，，： | 1 |
| 7 | Directions of change in land cover and landscape patterns from 1957 to 2000 in agricultural landscapes in NW Spain显示文摘 | Maria S Urbano F Rafael C | 2006 | Environmental Management2006，38，： | 1 |
| 8 | Characterization of Various Magnesium Oxides by XRD and 1HMAS NMR Spectroscopy显示文摘 | María Angeles Aramendía José Antonio Benítez Victoriano Borau César Jiménez José Maria Marinas José Rafael Ruiz and Francisco Urbano | 1999 | J Solid State Chem1999，144，1： | 1 |
| 9 | X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients显示文摘 | Maria J. Lamas Goretti Duran Antonio Gomez Emilia Balboa Urbano Anido Beatriz Bernardez Pablo Rana-Diez Rafael Lopez Angel Carracedo Francisco Barros | 2012 | International Journal of Radiation Oncology Biology Physics2012，，1： | 1 |
| 10 | Evaluation of Viability of Lactobacillus fermentum CECT 5716 in Gelatin and Gastroresistant Capsules显示文摘 | Maria Teresa Sanchez Rodriguez Herminia Castan Urbano Dolores Munoz de los Rios Ferderico Lara-Villoslada Maria Adolfina Ruiz Martinez Maria Encamacion Morales Hernandez | 2016 | Journal of Pharmacy and Pharmacology2016，4，8： | 0 |
| 11 | Evaluation of ^(177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors显示文摘BACKGROUND^177Lu peptide receptor radionuclide therapy(PRRT)is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine tumors.AIM To determine the impact of PRRT on quality of life,radiologic and metabolic response,overall survival,prognostic factors and toxicity.METHODS Thirty-six patients treated with^177Lu-PRRT from 2016 to 2019 were included.The most frequent location of the primary tumor was the gastrointestinal tract(52.8%),pancreas(27.8%),and nongastropancreatic neuroendocrine tumor(11.1%).The liver was the most common site of metastasis(91.7%),followed by distant nodes(50.0%),bone(27.8%),peritoneum(25.0%)and lung(11.1%).Toxicity was evaluated after the administration of each dose.Treatment efficacywas evaluated by two parameters:stable disease and disease progression in response evaluation criteria in solid tumors 1.1 criterion and prognostic factors were tested.RESULTS From 36 patients,55.6%were men,with a median age of 61.1±11.8 years.Regarding previous treatments,55.6%of patients underwent surgery of the primary tumor,100%of patients were treated with long-acting somatostatin analogues,66.7%of patients were treated with everolimus,27.8%of patients were treated with tyrosine kinase inhibitor,and 27.8%of patients were treated with interferon.One patient received radioembolization,three patients received chemoembolization,six patients received chemotherapy.Hematological toxicity was registered in 14 patients(G1-G2:55.5%and G3:3.1%).Other events presented were intestinal suboclusion in 4 cases,cholestasis in 2 cases and carcinoid crisis in 1 case.The median follow-up time was 3 years.Currently,24 patients completed treatment.Nineteen are alive with stable disease,two have disease progression,eight have died,and nine are still receiving treatment.The median overall survival was 12.5 mo(95%confidence interval range:9.8–15.2),being inversely proportional to toxicity in previous treatments(P<0.02),tumor grade(P<0.01)and the presence of bone lesions(P=0.009)and directly proportional with matching lesion findings between Octreoscan and computed tomography pre-PRRT(P<0.01),,primary tumor surgery(P=0.03)and metastasis surgery(P=0.045).In a multivariate Cox regression analysis,a high Ki67 index(P=0.003),a mismatch in the lesion findings between Octreoscan and computed tomography pre-PRRT(P<0.01)and a preceding toxicity in previous treatments(P<0.05)were risk factors to overall survival.CONCLUSION Overall survival was inversely proportional to previous toxicity,tumor grade and the presence of bone metastasis and directly proportional to matching lesion findings between Octreoscan and computed tomography pre-PRRT and primary tumor and metastasis surgery. | Estephany Abou Jokh Casas Virginia Pubul Núnez Urbano Anido-Herranz María del Carmen Mallón Araujo Maria del Carmen Pombo Pasín Miguel Garrido Pumar José Manuel Cabezas Agrícola José Manuel Cameselle-Teijeiro Ashraf Hilal álvaro Ruibal Morell | 2020 | World Journal of Gastroenterology2020，26，13： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员